The University of Illinois at Chicago is a member of several nationwide, multi-site clinical trial networks, including the American Lung Association Airways Clinical Research Centers (ACRC), the Pulmonary Trials Cooperative (PTC), The PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network and AsthmaNet, all of which are National Institutes of Health (NIH) funded networks initiated to conduct both adult and pediatric clinical trials in asthma.
ASTHMA TRIALS BEING CONDUCTED BY THE BCC
The Precision Interventions for Severe and/or Exacerbation-Prone Asthma Network (PrecISE) is a five-year study sponsored by the National Heart, Lung, and Blood Institute (NHLBI). The study aims to identify more effective treatments for severe asthma which affects nearly 10% of people worldwide, and remains poorly controlled for many patients. The study is an innovative clinical trial that will support a personalized medicine approach to identifying therapies which are tailored to an individual’s disease and treatment history.
For more information about PRECISE, contact us at 1-855-I-WHEEZE (1-855-494-3393) or via email at firstname.lastname@example.org.
SIENASteroids In Eosinophil Negative Asthma
The Steroids in Eosinophil Negative Asthma (SIENA) Study is a National Institutes of Health (NIH) sponsored study for adolescents and adults with mild to moderate asthma. The purpose of this study is to find out what medications work best for patients with different types of asthma. In this study we are testing whether people benefit from taking an inhaled corticosteroid (i.e. Flovent) versus a long-acting muscarinic antagonist (i.e. Spiriva) based on the type of inflammatory cells in their airways. The study involves 9-12 clinic visits over 1 year (about 1 visit per month) during which participants take inhalers provided by the study and keep track of their asthma symptoms using an “e-diary”.
For more information about SIENA, contact us at 1-855-I-WHEEZE (1-855-494-3393) or via email at email@example.com.
IndividualizedTherapy For Asthma in Toddlers (INFANT) / Acetaminophen Vs. Ibuprofen in Children with Asthma (AVICA)
INFANT and AVICA were two separate but linked studies for preschool aged children with persistent asthma. INFANT was designed to determine whether one asthma controller-medication worked better than another for these children, and to see if there were characteristics about a child that helped doctors predict which treatment would work better. AVICA was designed to find out if different fever/pain medicines have an effect on asthma symptoms.
We are pleased that the INFANT and AVICA studies were recently published.
BestAfrican American Response to Asthma Drugs (BARD)
BARD is a clinical trial for children, adolescents, and adults of African ancestry with poorly controlled asthma. The goal of BARD is to find out which asthma treatment, at what dose, works best for self-identified Blacks. BARD is closed to enrollment. Check back soon for results!
STICSSTep-up Yellow Zone Inhaled CorticosteroidS to Prevent Exacerbations
STICS is a pediatric study for children with moderate asthma. The goal of the STICS study is to determine whether quadrupling the dose of inhaled corticosteroids at the onset of asthma symptoms reduces the rate of severe asthma exacerbations treated with oral corticosteroids. STICS is closed to enrollment. Check back soon for results!
VItaminD add-on therapy enhances corticosteroid responsiveness in Asthma (VIDA)
VIDA was a clinical trial for adults with asthma and vitamin D deficiency. The goal of VIDA was to find out if taking Vitamin D in addition to an inhaled steroid helped to prevent worsening asthma symptoms and asthma exacerbations. Results for the VIDA study were published in the Journal of the American Medical Association (JAMA) in May, 2014 and were presented at the American Thoracic Society International Conference. Read the results here: VIDA.JAMA.2014
PRRPulmonary Research Registry
We offer UI Health patients and community members the opportunity to join the Pulmonary Research Registry (PRR). The registry is akin to a sign-up list for people who want to hear about exciting new research at UIC. As part of the PRR, you receive a quarterly newsletter packed with useful information and resources.